Personalising eye consultations to improve outcomes in diabetic retinopathy

Not Applicable

• Conditions: Diabetic retinopathy; Poor glycaemic control; Eye - Diseases / disorders of the eye; Metabolic and Endocrine - Diabetes; Public Health - Health promotion/education

• Registration Number: ACTRN12615000095561
• Lead Sponsor: Centre for Eye Research Australia (University of Melbourne)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 186

Inclusion Criteria

Inclusion criteria will be: (a) diagnosis of type 2 diabetes. We have chosen to focus only on type 2 diabetes given the epidemic of type 2 diabetes, and also as most of our public DR patients have this form. Additionally, we wish to keep our sample as homogenous as possible given the natural history and management of type 2 is very different from type 1 diabetes; (b) a score of 20-51 on the Early Treatment Diabetic Retinopathy Study (ETDRS) grading scale suggesting mild to moderate non proliferative diabetic retinopathy; (c) suboptimal HbA1c (greater than or equal to 8%)) at baseline assessment. We chose a conservative 8% cut-off point for our study to reach those in greatest need and to avoid adverse consequences (hypoglycaemia) of tight control; (d) no previous treatment for diabetic retinopathy (e.g., laser or anti-vascular endothelial growth factor) or indication of imminent treatment; (e) at least 18 years old; (f) no cognitive deficit, as assessed by the 6-item cognitive impairment test; (g) ability to communicate in English.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycosylated haemoglobin (HbA1c) result obtained from a blood test[Outcome will be assessed at baseline and 3 months, 6 months and 12 months follow-up. ]; Fasting blood glucose obtained from a blood test[Outcome will be assessed at baseline and 3 months, 6 months and 12 months follow-up. ]